NO20033911L - Somatostatin antagonister - Google Patents

Somatostatin antagonister

Info

Publication number
NO20033911L
NO20033911L NO20033911A NO20033911A NO20033911L NO 20033911 L NO20033911 L NO 20033911L NO 20033911 A NO20033911 A NO 20033911A NO 20033911 A NO20033911 A NO 20033911A NO 20033911 L NO20033911 L NO 20033911L
Authority
NO
Norway
Prior art keywords
aer
optionally substituted
amino acid
alkyl
group
Prior art date
Application number
NO20033911A
Other languages
English (en)
Norwegian (no)
Other versions
NO20033911D0 (no
Inventor
David H Coy
William Andrew Murphy
Walajapet G Rajeswaran
Original Assignee
Univ Tulane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tulane filed Critical Univ Tulane
Publication of NO20033911D0 publication Critical patent/NO20033911D0/no
Publication of NO20033911L publication Critical patent/NO20033911L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20033911A 2001-03-08 2003-09-04 Somatostatin antagonister NO20033911L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27430801P 2001-03-08 2001-03-08
PCT/US2002/006676 WO2002072602A2 (en) 2001-03-08 2002-03-05 Somatostatin antagonists

Publications (2)

Publication Number Publication Date
NO20033911D0 NO20033911D0 (no) 2003-09-04
NO20033911L true NO20033911L (no) 2003-10-29

Family

ID=23047655

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033911A NO20033911L (no) 2001-03-08 2003-09-04 Somatostatin antagonister

Country Status (16)

Country Link
US (3) US7378488B2 (hu)
EP (1) EP1372688B1 (hu)
JP (3) JP4204322B2 (hu)
AR (1) AR035942A1 (hu)
AT (1) ATE394114T1 (hu)
AU (1) AU2002258465B2 (hu)
CA (1) CA2439498A1 (hu)
CZ (1) CZ299362B6 (hu)
DE (1) DE60226419D1 (hu)
DK (1) DK1372688T3 (hu)
ES (1) ES2306766T3 (hu)
HU (1) HUP0401535A3 (hu)
NO (1) NO20033911L (hu)
PL (1) PL362838A1 (hu)
RU (2) RU2328504C2 (hu)
WO (1) WO2002072602A2 (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100707408B1 (ko) * 2000-10-20 2007-04-13 더 어드미니스트레이터즈 오브 더 튜래인 어듀케이셔널 훤드 유로텐신-ⅱ 작용제 및 길항제
CA2439498A1 (en) 2001-03-08 2002-09-19 The Administrators Of The Tulane Educational Fund Somatostatin antagonists
HUP0303727A2 (hu) * 2001-04-09 2004-03-01 The Administrators Of The Tulane Educational Fund Szomatosztatin agonisták és ezek alkalmazása
EP1522311A1 (fr) 2003-10-10 2005-04-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Utilisation de la somatostine ou d'un de ses analogues pour préparer un médicament destiné à réguler la réserve folliculaire ovarienne chez la femme non ménopausée
WO2006063465A1 (en) * 2004-12-15 2006-06-22 Diamedica Inc. Treatment of insulin resistance by modulating somatostatin using somatostatin receptor antagonists
US8691761B2 (en) 2006-10-16 2014-04-08 Jean E. F. Rivier Somatostatin receptor 2 antagonists
PL2076535T3 (pl) * 2006-10-16 2013-08-30 Salk Inst Biological Studies Antagoniści somatostatyny selektywni względem receptora (SSTR2)
EP2168983A1 (fr) 2008-09-30 2010-03-31 Ipsen Pharma Nouveaux composés octapeptidiques et leur utilisation thérapeutique
EP2351848B1 (en) * 2008-10-29 2018-02-28 Kaneka Corporation Method for producing l-amino acid
EP2399931A1 (fr) * 2010-06-22 2011-12-28 Ipsen Pharma S.A.S. Nouveaux composés octapeptidiques et leur utilisation thérapeutique
KR20180117636A (ko) 2016-02-09 2018-10-29 씨디알디 벤쳐스 인코포레이티드 소마토스타틴 수용체 길항제 화합물 및 이의 이용 방법
WO2021111503A1 (ja) * 2019-12-02 2021-06-10 花王株式会社 光吸収層及びその製造方法、分散液、光電変換素子、並びに太陽電池

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0098457B1 (en) * 1980-02-14 1987-08-05 Sandoz Ag (1s,2r,3r)- and (1r,2s,3s)-nitrilo-1-carbonyl-3-methyl-2-oxy-heptanes and -hept-5-enes useful in the total synthesis of cyclosporins and processes for their production
JPS63146850A (ja) 1986-11-12 1988-06-18 メルク　エンド　カムパニー　インコーポレーテツド フエニルアラニル−ヒスチジン代用成分を有するレニン阻害剤
EP0278158A3 (en) 1986-11-12 1990-05-23 Merck & Co. Inc. Renin inhibitors containing phenylalanyl-histidine replacements
EP0273696A2 (en) 1987-01-02 1988-07-06 Merck & Co. Inc. Renin inhibitors containing histidine replacements
CH679045A5 (hu) 1987-06-29 1991-12-13 Sandoz Ag
JPS6426599U (hu) 1987-08-10 1989-02-15
EP0328090A3 (en) 1988-02-10 1990-08-16 Abbott Laboratories Lhrh analogs
DK0457888T3 (da) * 1989-12-08 1996-08-12 Univ Tulane Octapeptidanaloger af somatostatin med threonin i 6-stillingen
US7223833B1 (en) * 1991-05-24 2007-05-29 Isis Pharmaceuticals, Inc. Peptide nucleic acid conjugates
EP0592512A1 (en) 1991-07-01 1994-04-20 University Technologies International Inc. (Uti) NON-DESENSITIZING ANALOGS OF GnRH AND OTHER BIOLOGICALLY ACTIVE LIGANDS
JP3480848B2 (ja) * 1992-06-19 2003-12-22 タカラバイオ株式会社 環状ペプチドの合成方法
US5569741A (en) * 1992-07-27 1996-10-29 Biomeasure, Inc. Cyclic octapeptide neuromedin B receptor antagonists
ATE284413T1 (de) * 1993-08-09 2004-12-15 Sod Conseils Rech Applic Therapeutische peptid derivate
GB9402767D0 (en) 1994-02-14 1994-04-06 Sandoz Ltd Improvements in or relating to organic compounds
US5696230A (en) * 1994-08-31 1997-12-09 The Board Of Regents Of The University Of Nebraska High-affinity response-selective C-terminal analogs of C5a anaphylatoxin
US5750499A (en) * 1995-10-18 1998-05-12 The Salk Institute For Biological Studies Receptor-selective somatostatin analogs
US5846934A (en) * 1996-02-20 1998-12-08 American Cyanamid Company Pure somatostatin antagonist and methods of use thereof
US6355613B1 (en) * 1996-07-31 2002-03-12 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
WO1998008528A1 (en) 1996-08-30 1998-03-05 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
AU4133997A (en) * 1996-09-12 1998-04-02 Yarom Cohen Pharmaceutical composition for the treatment of syndrome x of reaven
KR100479149B1 (ko) 1996-12-04 2005-03-25 더 어드미니스트레이터즈 오브 더 튜래인 어듀케이셔널 훤드 소마토스타틴 길항제
US6887470B1 (en) * 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
DE60220157T2 (de) * 2001-03-06 2008-01-17 Il Consorzio Ferrara Richerche Verfahren zur modulierung der proliferation von medullären schilddrüsen-karzinomzellen
CA2439498A1 (en) 2001-03-08 2002-09-19 The Administrators Of The Tulane Educational Fund Somatostatin antagonists
HUP0303727A2 (hu) 2001-04-09 2004-03-01 The Administrators Of The Tulane Educational Fund Szomatosztatin agonisták és ezek alkalmazása

Also Published As

Publication number Publication date
ES2306766T3 (es) 2008-11-16
WO2002072602A2 (en) 2002-09-19
US7408024B2 (en) 2008-08-05
US20080171853A1 (en) 2008-07-17
CZ20032281A3 (cs) 2004-01-14
DK1372688T3 (da) 2008-08-25
US7378488B2 (en) 2008-05-27
RU2263678C2 (ru) 2005-11-10
HUP0401535A3 (en) 2009-07-28
RU2005117614A (ru) 2006-11-20
JP2008255120A (ja) 2008-10-23
PL362838A1 (en) 2004-11-02
US20040181032A1 (en) 2004-09-16
NO20033911D0 (no) 2003-09-04
JP4204322B2 (ja) 2009-01-07
CZ299362B6 (cs) 2008-07-02
EP1372688A4 (en) 2006-06-14
EP1372688A2 (en) 2004-01-02
HUP0401535A2 (hu) 2004-12-28
WO2002072602A3 (en) 2003-03-20
AR035942A1 (es) 2004-07-28
RU2003129807A (ru) 2005-03-20
JP2004532824A (ja) 2004-10-28
AU2002258465B2 (en) 2006-01-19
ATE394114T1 (de) 2008-05-15
CA2439498A1 (en) 2002-09-19
EP1372688B1 (en) 2008-05-07
RU2328504C2 (ru) 2008-07-10
US20080020970A1 (en) 2008-01-24
JP2006342171A (ja) 2006-12-21
DE60226419D1 (de) 2008-06-19

Similar Documents

Publication Publication Date Title
NO20033911L (no) Somatostatin antagonister
ATE230392T1 (de) Amidinophenyl-pyrrolidine, -pyrroline und - isoxazolidine und ihre derivate
JO2371B1 (en) 4-phenyl-pyridine derivatives
IS6275A (is) Heteróhringa efnasambönd og notkun þeirra sem mótlyf efnaskiptaglútamatviðtaka
NO20052307L (no) Blandinger og fremgangsmater for a modifisere toksiske effekter av proteinlignende forbindelser.
NO20003133D0 (no) Anilidderivater, fremstilling og anvendelse derav
RS51444B (sr) JEDINJENJA KOJA SADRŽE LAKTAM I NJIHOVI DERIVATI KAO INHIBITORI FAKTORA Xa
MY119689A (en) Pyrazolopyridine derivatives
SE9301911D0 (sv) New peptide derivatives
ZA967379B (en) Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid compounds and derivatives thereof.
HUP0303727A2 (hu) Szomatosztatin agonisták és ezek alkalmazása
EA200300527A1 (ru) Новые способы лечения синдрома "усталых ног"
CY1111951T1 (el) Φαινυλο-καρβοξαμιδικες ενωσεις χρησιμες για την αντιμετωπιση πονου
ATE394383T1 (de) Biphenylkarbonsäureamidderivate als p38 kinase- inhibitoren
BR9910119A (pt) Derivados heterocìclicos de glicil beta-alanina como antagonistas de vitronectina
NO985518L (no) Morfinanderivater og medisinsk anvendelse derav
JO2321B1 (en) 4-phenyl-pyridine derivatives
BG104740A (en) Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists
ATE402175T1 (de) 4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1, - naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren
EA200400280A1 (ru) Новые неочищенные и кристаллические формы гидрохлорида лерканидипина
RS50879B (sr) Kristalna natrijumova so telmisartana i njena primena kao angiotenzinskog antagonista
BR0317487A (pt) O r-isÈmero de compostos de aminoácido beta como derivados de antagonistas de receptores de integrina
EA200300392A1 (ru) Производные пиперазина с мостиковой связью
EE200100520A (et) N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena
RU2006106721A (ru) Получение пептидов соматостатина

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application